SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Eli Lilly Presents First Ovarian Cancer Data for Investigational ADC

At ESMO 2026, Eli Lilly reported that sofe-M plus bevacizumab demonstrated a 79% confirmed objective response rate in platinum-sensitive ovarian cancer.

LLY

Related stories